Suppr超能文献

曲唑酮治疗失眠症:随机安慰剂对照试验的荟萃分析。

Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials.

机构信息

The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Sleep Med. 2018 May;45:25-32. doi: 10.1016/j.sleep.2018.01.010. Epub 2018 Feb 7.

Abstract

OBJECTIVE

To assess the efficacy and tolerability of trazodone compared with placebo in patients with insomnia.

METHODS

Electronic databases were searched and relevant reports were hand-screened to identify eligible trials. Only randomized placebo-controlled trials were included. Standardized mean differences (SMD) and the odds ratios (OR) were estimated using a random-effect model. Primary efficacy outcomes included sleep efficiency (SE%) and self-reported sleep quality (SQ). Secondary efficacy outcomes included sleep latency (SL), total sleep time (TST), the number of awakenings (NAs), waking time after sleep onset (WASO). Tolerability outcome was measured by the number of patients who discontinued for adverse events and acceptability outcome was measured by the number of patients who discontinued for all causes.

RESULTS

Seven trials involving 429 patients were included. There was no significant improvement for trazodone in SE% (SMD = 0.09, 95% confidence interval (CI) -0.19 to 0.38, P = 0.53) with a non-significant heterogeneity (I = 0%, P = 0.59). However, patients receiving trazodone perceived better SQ than those receiving the placebo (SMD = -0.41, 95% CI -0.82 to -0.00, P = 0.05) with a non-significantly moderate heterogeneity (I = 65%, P = 0.06). As to secondary efficacy outcomes, we only found a significant reduction for trazodone in NAs (SMD = -0.51, 95%CI -0.97 to -0.05) compared to the placebo, with non-significant differences found in SL, TST, or WASO between trazodone and placebo. Moreover, no significant difference was found in the outcome of tolerability or acceptability.

CONCLUSIONS

Trazodone was effective in sleep maintenance by decreasing the number of early awakenings and it could significantly improve perceived sleep quality, although there were no significant improvements in sleep efficiency or other objective measures. Trazodone however, presented good tolerance in the short-term treatment of insomnia.

摘要

目的

评估曲唑酮治疗失眠的疗效和耐受性,并与安慰剂进行比较。

方法

检索电子数据库并手工筛选相关报告,以确定合格的试验。仅纳入随机安慰剂对照试验。使用随机效应模型估计标准化均数差(SMD)和比值比(OR)。主要疗效结局包括睡眠效率(SE%)和自我报告的睡眠质量(SQ)。次要疗效结局包括睡眠潜伏期(SL)、总睡眠时间(TST)、觉醒次数(NAs)和睡眠起始后醒来时间(WASO)。耐受性结局通过因不良事件而停药的患者人数来衡量,可接受性结局通过因所有原因而停药的患者人数来衡量。

结果

纳入 7 项涉及 429 名患者的试验。曲唑酮在 SE%方面无显著改善(SMD=0.09,95%置信区间(CI)-0.19 至 0.38,P=0.53),且异质性无统计学意义(I=0%,P=0.59)。然而,接受曲唑酮治疗的患者感知到的睡眠质量明显优于接受安慰剂的患者(SMD=-0.41,95%CI-0.82 至-0.00,P=0.05),且异质性中度但无统计学意义(I=65%,P=0.06)。至于次要疗效结局,我们仅发现曲唑酮组的觉醒次数明显减少(SMD=-0.51,95%CI-0.97 至-0.05),与安慰剂相比,曲唑酮组和安慰剂组的 SL、TST 或 WASO 无显著差异。此外,在耐受性或可接受性结局方面未发现显著差异。

结论

曲唑酮通过减少早期觉醒次数对睡眠维持有效,可显著改善感知的睡眠质量,尽管睡眠效率或其他客观测量指标无显著改善。然而,曲唑酮在失眠的短期治疗中具有良好的耐受性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验